Ultimovacs ASA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was NOK 189.24 million compared to NOK 167.79 million a year ago. Basic loss per share from continuing operations was NOK 5.5 compared to NOK 4.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.93 NOK | -1.42% | -1.84% | -94.36% |
May. 07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-94.36% | 21.98M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs ASA Reports Earnings Results for the Full Year Ended December 31, 2023